PA
DYN icon

Parallel Advisors’s Dyne Therapeutics DYN Stock Holding History

Parallel Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$600 Hold
27
– – ﹤0.01% 3765
2026
Q1 		$490 Hold
27
– – ﹤0.01% 3676
2025
Q4 		$528 Hold
27
– – ﹤0.01% 3394
2025
Q3 		$342 Sell
27
-35
-56% -$399 ﹤0.01% 3380
2025
Q2 		$590 Buy
62
+35
+130% +$385 ﹤0.01% 3288
2025
Q1 		$282 Hold
27
– – ﹤0.01% 3337
2024
Q4 		$636 Sell
27
-1
-4% -$30 ﹤0.01% 3182
2024
Q3 		$1.01K Buy
28
+1
+4% +$40 ﹤0.01% 3035
2024
Q2 		$953 Buy
+27
New +$785 ﹤0.01% 2972

Other funds holding DYN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Parallel Advisors's DYN Position: Q2 2026 in Review

Parallel Advisors held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 27 shares worth $600. The position accounts for ﹤0.01% of the portfolio, ranked #3765.

Parallel Advisors first reported a position in DYN in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.01K in Q3 2024. 76 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Parallel Advisors held 27 shares of Dyne Therapeutics worth $600 as of Q2 2026.
  • Parallel Advisors left its Dyne Therapeutics share count unchanged in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3765 holding.
  • Parallel Advisors first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Parallel Advisors's Dyne Therapeutics position peaked at $1.01K in Q3 2024.
  • 76 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.